Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Thrombin-Induced PARI Signaling Pathway Modulates ß-Catenin in the Transformation of Symptomatic Myeloma Cells Into the Quiescent Phenotype,

Erming Tian, PhD, Saad Usmani, MD, FACP, Yiming Zhou, PhD, Bart Barlogie, MD, Ph.D, John D Shaughnessy, Jr., PhD

Blood (2011) 118 (21): 3932.

https://doi.org/10.1182/blood.V118.21.3932.3932

Published: 2011

Journal Articles

Deregulated Cellular Iron Metabolism Factors Mediate Iron Overload in Myeloma Cells and Osteoclasts, and Promote Myeloma Growth and Bone Disease,

Rakesh Bam, Wen Ling, MS, Sharmin Khan, MS, Sathisha Upparahalli Venkateshaiah, PhD, Xin Li, PhD, Frits van Rhee, MD, PhD, Bijay Nair, MD, Saad Usmani, MD, FACP, Bart Barlogie, MD, PhD, John D Shaughnessy, Jr., PhD, Joshua Epstein, DSc, Elias J. Anaissie, MD, Shmuel Yaccoby, PhD

Blood (2011) 118 (21): 3941.

https://doi.org/10.1182/blood.V118.21.3941.3941

Published: 2011

Journal Articles

Pomalidomide (Pom) in Relapsed and Refractory Multiple Myeloma (RRMM) - theUARK Compassionate Use Protocol,

Saad Usmani, MD, FACP, Sarah Waheed, MD, Jackie Szymonifka, Susan Panozzo, Nathan M Petty, Doug Steward, Bijay Nair, MD, Yazan Alsayed, MD, Antje Hoering, PhD, John Crowley, PhD, Bart Barlogie, MD, Ph.D

Blood (2011) 118 (21): 3995.

https://doi.org/10.1182/blood.V118.21.3995.3995

Published: 2011

Journal Articles

SWOG S0120 Observational Trial for MGUS and Asymptomatic Multiple Myeloma (AMM): Imaging Predictors of Progression for Patients Treated At UAMS,

Christoph Heuck, MD, Rachael Sexton, Madhav Dhodapkar, MD, MBBS, Qing Zhang, PhD, Saad Usmani, MD, FACP, Bijay Nair, MD, Frits van Rhee, MD, PhD, Antje Hoering, PhD, John Crowley, PhD, John D Shaughnessy, Jr., PhD, Robert Z. Orlowski, MD, PhD, Bart Barlogie, MD, PhD

Blood (2011) 118 (21): 3955.

https://doi.org/10.1182/blood.V118.21.3955.3955

Published: 2011

Journal Articles

Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease,

Razelle Kurzrock, MD, Peter M. Voorhees, MD, Corey Casper, MD, Richard R. Furman, MD, Luis Fayad, MD, Sagar Lonial, MD, Hossein Borghaei, DO, Sundar Jagannath, MD, Lubomir Sokol, MD, PhD, Saad Usmani, MD, FACP, Helgi van de Velde, MD, PhD, Xiang Qin, PhD, Ming Qi, MD, PhD, Mark J. Cornfeld, MD, MPH, Frits van Rhee, MD, PhD

Blood (2011) 118 (21): 3959.

https://doi.org/10.1182/blood.V118.21.3959.3959

Published: 2011

Journal Articles

A Better Mobilization Regimen for Newly Diagnosed Multiple Myeloma Patients,

Ahmed Y Abuabdou, MD, Eric R Rosenbaum, MD, MPH, Saad Usmani, MD, FACP, Bart Barlogie, MD, Ph.D, Michele Cottler-Fox, MD

Blood (2011) 118 (21): 4051.

https://doi.org/10.1182/blood.V118.21.4051.4051

Published: 2011

Journal Articles

Jumping Translocations 1q12 Contribute to Copy Number (CN) Alterations in Multiple Myeloma (MM): Unexpected Focal Amplifications of Receptor Chromosomes (RC)

Jeffrey Sawyer, Erming Tian, PhD, John D. Shaughnessy, Jr., PhD, Janet Lukacs, Regina Lichti Binz, Edward Thomas, Gael Sammartino, Charles Swanson, Christoph Heuck, MD, Yazan Alsayed, MD, Elias J. Anaissie, MD, Bijay Nair, MD, Sarah Waheed, MD, Saad Usmani, MD, FACP, Frits van Rhee, MD, PhD, Bart Barlogie, MD, Ph.D

Blood (2011) 118 (21): 298.

https://doi.org/10.1182/blood.V118.21.298.298

Published: 2011

Journal Articles

Gene Expression Profiling (GEP) Analysis of Plasma Cells (PC) Obtained From MRI-Defined Focal Lesions (FL) Under CT-Guided Fine-Needle Aspiration Provides Better Risk Stratification in Patients with Multiple Myeloma

Qing Zhang, PhD, Pingping Qu, PhD, Emily Hansen, MS, Christoph Heuck, MD, Saad Usmani, MD, FACP, Bijay Nair, MD, Sarah Waheed, MD, Yazan Alsayed, MD, Antje Hoering, PhD, John Crowley, PhD, John D Shaughnessy, Jr., PhD, Bart Barlogie, MD, PhD

Blood (2011) 118 (21): 2896.

https://doi.org/10.1182/blood.V118.21.2896.2896

Published: 2011

Journal Articles

Phase II Study of Carfilzomib (CFZ) Combined with Other Anti-Myeloma Agents in Relapsed-Refractory Multiple Myeloma (RRMM) - Updates on the UARK Compassionate Use Protocol

Saad Usmani, MD, FACP, Jackie Szymonifka, Rachael Sexton, Susan Panozzo, Bijay Nair, MD, Sarah Waheed, MD, Yazan Alsayed, MD, John Crowley, PhD, Bart Barlogie, MD, Ph.D

Blood (2011) 118 (21): 2947.

https://doi.org/10.1182/blood.V118.21.2947.2947

Published: 2011

Journal Articles

Total Therapy 6: Initial Results of Dose-Dense Strategy for Previously Treated Multiple Myeloma

Saad Usmani, MD, FACP, Alan Mitchell, Bijay Nair, MD, Sarah Waheed, MD, Frits van Rhee, MD, PhD, Yazan Alsayed, MD, Nathan M Petty, Doug Steward, Susan Panozzo, Antje Hoering, PhD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2011) 118 (21): 3081.

https://doi.org/10.1182/blood.V118.21.3081.3081

Published: 2011

Journal Articles

Implications of Serial Magnetic Resonance Imaging and Positron Emission Tomography Scanning for Survival of Untreated Myeloma Patients Treated with Total Therapy 3

Saad Usmani, MD, FACP, Alan Mitchell, Rachael Sexton, Susan Panozzo, Bijay Nair, MD, Sarah Waheed, MD, Yazan Alsayed, MD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2011) 118 (21): 3082.

https://doi.org/10.1182/blood.V118.21.3082.3082

Published: 2011

Journal Articles

Cell Surface CXCR4 and BTK Expression Are Associated in Myeloma Cells and Osteoclast Precursors and Mediate Myeloma Cell Homing and Clonogenicity, and Osteoclastogenesis

Rakesh Bam, Wen Ling, Sharmin Khan, Angela Pennisi, MD, Sathisha Upparahalli Venkateshaiah, PhD, Xin Li, PhD, Ryan Williams, Frits van Rhee, MD, PhD, Bijay Nair, MD, Saad Usmani, MD, FACP, Bart Barlogie, MD, PhD, John D Shaughnessy, Jr., PhD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD

Blood (2011) 118 (21): 884.

https://doi.org/10.1182/blood.V118.21.884.884

Published: 2011

Journal Articles

Low Expression of Nuclear Glucocorticoid Receptor Gene NR3C1 in Newly Diagnosed Myeloma Correlates with Inferior Prognosis and Is Rescued by Thalidomide

Christoph Heuck, MD, Jackie Szymonifka, Qing Zhang, PhD, Saad Usmani, MD, FACP, Bijay Nair, MD, Sarah Waheed, MD, Yazan Alsayed, MD, Frits van Rhee, MD, PhD, Elias J. Anaissie, MD, Antje Hoering, PhD, John Crowley, PhD, John D Shaughnessy, Jr., PhD, Bart Barlogie, MD, PhD

Blood (2011) 118 (21): 988.

https://doi.org/10.1182/blood.V118.21.988.988

Published: 2011

Journal Articles

Second Malignancies in Total Therapy 3 Trials for Newly Diagnosed Multiple Myeloma: Influence of Lenalidomide Versus Thalidomide in Maintenance Phases

Saad Usmani, MD, FACP, Rachael Sexton, Antje Hoering, PhD, Christoph Heuck, MD, Bijay Nair, MD, Sarah Waheed, MD, Yazan Alsayed, MD, Nathan M Petty, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2011) 118 (21): 823.

https://doi.org/10.1182/blood.V118.21.823.823

Published: 2011

Journal Articles

Pharmacodynamic, Biodistribution and Toxicology Results for SNS01-T, a Nanoparticle That Targets eIF5A for the Treatment of Multiple Myeloma

Richard Dondero, Saad Usmani, MD, FACP, Catherine A Taylor, Zhongda Liu, Tang Terence, John Thompson

Blood (2011) 118 (21): 2051.

https://doi.org/10.1182/blood.V118.21.2051.2051

Published: 2011

NARROW

Thrombin-Induced PARI Signaling Pathway Modulates ß-Catenin in the Transformation of Symptomatic Myeloma Cells Into the Quiescent Phenotype,

Deregulated Cellular Iron Metabolism Factors Mediate Iron Overload in Myeloma Cells and Osteoclasts, and Promote Myeloma Growth and Bone Disease,

Pomalidomide (Pom) in Relapsed and Refractory Multiple Myeloma (RRMM) - theUARK Compassionate Use Protocol,

SWOG S0120 Observational Trial for MGUS and Asymptomatic Multiple Myeloma (AMM): Imaging Predictors of Progression for Patients Treated At UAMS,

Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease,

A Better Mobilization Regimen for Newly Diagnosed Multiple Myeloma Patients,

Jumping Translocations 1q12 Contribute to Copy Number (CN) Alterations in Multiple Myeloma (MM): Unexpected Focal Amplifications of Receptor Chromosomes (RC)

Gene Expression Profiling (GEP) Analysis of Plasma Cells (PC) Obtained From MRI-Defined Focal Lesions (FL) Under CT-Guided Fine-Needle Aspiration Provides Better Risk Stratification in Patients with Multiple Myeloma

Phase II Study of Carfilzomib (CFZ) Combined with Other Anti-Myeloma Agents in Relapsed-Refractory Multiple Myeloma (RRMM) - Updates on the UARK Compassionate Use Protocol

Total Therapy 6: Initial Results of Dose-Dense Strategy for Previously Treated Multiple Myeloma

Implications of Serial Magnetic Resonance Imaging and Positron Emission Tomography Scanning for Survival of Untreated Myeloma Patients Treated with Total Therapy 3

Cell Surface CXCR4 and BTK Expression Are Associated in Myeloma Cells and Osteoclast Precursors and Mediate Myeloma Cell Homing and Clonogenicity, and Osteoclastogenesis

Low Expression of Nuclear Glucocorticoid Receptor Gene NR3C1 in Newly Diagnosed Myeloma Correlates with Inferior Prognosis and Is Rescued by Thalidomide

Second Malignancies in Total Therapy 3 Trials for Newly Diagnosed Multiple Myeloma: Influence of Lenalidomide Versus Thalidomide in Maintenance Phases

Pharmacodynamic, Biodistribution and Toxicology Results for SNS01-T, a Nanoparticle That Targets eIF5A for the Treatment of Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only